Skip to main content
. 2020 Sep 23;10:15568. doi: 10.1038/s41598-020-72453-1

Table 3.

Occurrence of TAVR implantation related complications according to the available prosthesis.

Valve PPI (% ) NStudies/NPatients PVL II-III NStudies/NPatients Card. reint. (%) NStudies/NPatients Surg. replacement (%) NStudies/NPatients Balloon post-dilation (%) NStudies/NPatients Cor. Obs. (%) NStudies/NPatients
SAPIEN 7.09 ± 4.36 37/10,768 11.02 ± 7.22 12/3,435 2.40 1/419 3.04 ± 3.57 17/3,711 6.99 ± 9.70 12/1731 1.41 ± 2.11 7/826
SAPIEN XT 8.59 ± 3.41 40/13,008 4.89 ± 3.53 16/1934 2.65 ± 0.21 2/289 1.74 ± 1.40 16/2,937 15.80 ± 17.81 11/1,190 2.00 ± 1.21 4/900
SAPIEN 3 11.51 ± 4.48 26/5,948 2.04 ± 2.61 22/4,260 1.40 1/815 0.87 ± 2.17 10/3,711 5.33 ± 8.16 9/983 0.00 ± 0.00 8/952
CoreValve 25.38 ± 10.32 90/26,188 15.70 ± 9.64 45/12,481 1.15 ± 0.21 2/1,485 1.96 ± 2.90 21/12,673 24.25 ± 12.80 17/9,061 0.35 ± 0.64 11/5,127
LotusValve 28.64 ± 6.62 19/2,935 0.65 ± 1.27 11/1571 0.12/0.30 12/923 0.51 ± 1.44 13/942 n.a 0/0 0.48 ± 0.44 5/738
ACURATE Neo 7.10 ± 2.82 3/158 0.00 ± 0.00 4/132 3.40 1/89 0.275 ± 0.55 4/162 33.63 ± 8.97 3/44 0.00 ± 0.00 4/133
ACURATE TA 3.75 ± 5.30 2/50 0.00 ± 0.00 2/50 n.a 0/0 0.00 1/10 n.a 0/0 n.a 0/0
Portico 10.04 ± 3.77 5,484 2.38 ± 2.17 4/262 n.a 0/0 0.00 1/22 9.10 1/22 0.00 1/102
Direct flow medical 13.98 ± 6.79 9/960 1.25 ± 1.77 2/218 1.75 ± 1.65 6/512 6.68 ± 5.80 4/422 n.a 0/0 1.60 ± 2.62 2/281
JenaValve 14.40 1/180 0.00 1/27 n.a 0/0 2.80 1/180 n.a 0/0 0.00 1/180
Evolut R 14.08 ± 2.58 5/1,499 4.00 ± 3.42 5/1,499 0.150 ± 0.30 4/1,425 0.00 ± 0.00 2/146 21.70 1/60 0.10 ± 0.20 4/1,425
Engager 19.20 ± 8.83 3/101 0.00 1/30 n.a 0/0 10 1/30 3.30 1/30 n.a 0/0

PPI new permanent pacemaker implantation, PVL paravalvular leakage, Card.Reint. cardiac re-intervention, Cor.Obs. coronary obstruction.